Drugs / Yasmin
Yasmin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | YASMIN | — | 2001-05-11 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00714233 | Aug 2002 → Apr 2004 | polycystic ovary syndrome | University of Rochester | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02027337 | Dec 2013 → Mar 2015 | menstrual disorder, polycystic ovary syndrome | Tyumen State Medical Academy | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07318337 | Jul 2024 → Jun 2025 | polycystic ovary syndrome | Mst.Sumyara Khatun | Completed | No outcome recorded |
| — | NCT06577974 | Jul 2024 → Feb 2025 overdue | endometriosis | Cairo University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01603745 Comparator | Apr → May 2012 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| Phase 1 | NCT01195974 Background | Sep 2010 → Feb 2011 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05156879 Comparator | Dec 2021 → Dec 2024 | pelvis syndrome | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT03819140 Comparator | Apr 2019 → Oct 2022 | polycystic ovary syndrome | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02841202 Comparator | Jan 2014 → Dec 2015 | — | Kayseri Education and Research Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04296422 Comparator | Jan 2019 → Sep 2020 | premenstrual tension | Taipei City Hospital | Unknown | No outcome recorded |
| — | NCT03881319 Comparator | Jun 2018 → Dec 2019 | dysmenorrhea, premenstrual tension | Taipei City Hospital | Unknown | No outcome recorded |
| — | NCT02681536 Background | Feb → Sep 2016 | infertility disorder | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yasmin | “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.” NCT03881319 ↗8“Yasmin(Drospirenone ethinyl estradiol tablet) will be used as positive control.” NCT05156879 ↗ “Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks” NCT00714233 ↗ “Oral contraceptives include Yasmin.” NCT04296422 ↗ “yasmin” NCT02841202 ↗ |
| Known as | Combined oral contraceptive pills | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02681536 ↗ |
| Known as | Drospirenone ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156879 ↗ |
| Known as | Selmevit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02027337 ↗ |
| Route | Oral | “Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks” NCT00714233 ↗ |